Scholarlink

Background <p>Patients with immunodeficiency syndromes associated with anti-interferon-gamma (IFN-γ) autoantibodies are prone to a wide range of infections, particularly those caused by intracellular pathogens such as nontuberculous mycobacteria (NTM) or <i>Talaromyces marneffei</i> (<i>T. marneffei</i>). However, disseminated <i>Mycobacterium kansasii</i> (<i>M. kansasii</i>) infection co-occurring with <i>T. marneffei</i> infection is relatively rare. Here, we present a case of disseminated <i>M. kansasii</i> disease complicated by <i>T. marneffei</i> infection in a patient with anti-IFN-γ autoantibodies.</p> Case presentation <p>A 52-year-old man presented with a persistent cough, back pain, fever, generalized rash, and multiple enlarged lymph nodes. Chest computed tomography (CT) revealed hilar Masses, and technetium 99m (Tc-99m) skeletal scintigraphy showed multifocal increased osteoblastic activity. Histopathological examination of the hilar mass biopsy specimens revealed chronic suppurative inflammation. Metagenomic next-generation sequencing (mNGS) of the right submandibular lymph node identified <i>M. kansasii</i>, while blood culture isolated <i>T. marneffei</i>. The patient was diagnosed with disseminated <i>M. kansasii</i> infection co-existing with <i>T. marneffei</i> infection. Additionally, he tested positive for anti-IFN-γ autoantibodies. Combination therapy for NTM-comprising isoniazid, clarithromycin, moxifloxacin, and linezolid—in conjunction with antifungal therapy (amphotericin B followed by itraconazole) achieved a favorable clinical outcome.</p> Conclusions <p>Patients with anti-IFN-γ autoantibodies are at risk of developing multiple opportunistic bacterial infections, which may occur concurrently or sequentially, complicating diagnosis. Early detection using mNGS is critical in these cases, as it enables timely therapeutic adjustments and improves clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disseminated Mycobacterium kansasii disease complicating Talaromyces marneffei infection in patient with anti-IFN-γ autoantibodies: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Sufang Wei,
  • Dali Meng,
  • Jinyu Qin,
  • Shenglin Mo,
  • Zhongsheng Jiang,
  • Peng Zhang

摘要

Background

Patients with immunodeficiency syndromes associated with anti-interferon-gamma (IFN-γ) autoantibodies are prone to a wide range of infections, particularly those caused by intracellular pathogens such as nontuberculous mycobacteria (NTM) or Talaromyces marneffei (T. marneffei). However, disseminated Mycobacterium kansasii (M. kansasii) infection co-occurring with T. marneffei infection is relatively rare. Here, we present a case of disseminated M. kansasii disease complicated by T. marneffei infection in a patient with anti-IFN-γ autoantibodies.

Case presentation

A 52-year-old man presented with a persistent cough, back pain, fever, generalized rash, and multiple enlarged lymph nodes. Chest computed tomography (CT) revealed hilar Masses, and technetium 99m (Tc-99m) skeletal scintigraphy showed multifocal increased osteoblastic activity. Histopathological examination of the hilar mass biopsy specimens revealed chronic suppurative inflammation. Metagenomic next-generation sequencing (mNGS) of the right submandibular lymph node identified M. kansasii, while blood culture isolated T. marneffei. The patient was diagnosed with disseminated M. kansasii infection co-existing with T. marneffei infection. Additionally, he tested positive for anti-IFN-γ autoantibodies. Combination therapy for NTM-comprising isoniazid, clarithromycin, moxifloxacin, and linezolid—in conjunction with antifungal therapy (amphotericin B followed by itraconazole) achieved a favorable clinical outcome.

Conclusions

Patients with anti-IFN-γ autoantibodies are at risk of developing multiple opportunistic bacterial infections, which may occur concurrently or sequentially, complicating diagnosis. Early detection using mNGS is critical in these cases, as it enables timely therapeutic adjustments and improves clinical outcomes.